The Ewing's sarcoma family of tumors (ESFT) contain a translocation, t(11;22), which results in the novel oncogenic fusion protein EWS/FLI1. Platelet-derived growth factors (PDGF) and their receptors (PDGFR) are involved in the induction and proliferation of numerous solid tumors and are the potential candidates for novel targeted antitumor therapy. Since a relation was reported between PDGF-C and EWS/FLI1, we sought to characterize the PDGF signaling pathway in ESFT. Eight out of nine ESFT cell lines were found to express significant levels of b-PDGFR. Interestingly, none of the tested cell lines expressed a-PDGFR, which is the receptor isotype required for PDGF-C binding. By immunohistochemical staining 47 of 52 (90.4%) archival tumor samples from patients with ESFT were positive for b-PDGFR. ESFT cell lines were treated with PDGF-AA or PDGF-BB ligands to evaluate downstream signaling. Autophosphorylation of b-PDGFR and tyrosine phosphorylation of PLC-c, PI3Kp85 and Shc were detected only in PDGF-BB-stimulated cells that express b-PDGFR. Receptor function was further evaluated using chemotaxis assays that showed TC-32 cell migration towards PDGF-BB. A specific PDGFR kinase inhibitor AG1295 blocked b-PDGFR activation, downstream signaling, growth in cell culture and chemotaxis of TC-32 cells. AG1295 also delayed tumor formation and prolonged survival in an ESFT animal model. We conclude that ESFT express b-PDGFR and that this is a functional and potentially crucial signaling pathway. Therefore, b-PDGFRs may provide a novel therapeutic target in ESFT that can be utilized to design better treatment modalities.
Introduction
The Ewing's sarcoma family of tumors (ESFT) affect patients between ages of 3 and 40 years, with most cases occurring in the second decade of life (Grier, 1997; Denny, 1998) . ESFT contain a characteristic chromosomal translocation, t(11;22), which is present in 90-95% of the tumors. The resulting fusion protein, EWS/ FLI1, contains the amino-terminal of EWS and the carboxy-terminal of FLI1. Patients presenting with localized disease have a significantly better survival rate (in the range 60-70%) than patients with metastatic disease (Miser et al., 1996) . Treatment of metastatic tumors has been unsuccessful despite new high-dose chemotherapeutic regimens with stem cell rescue (Meyers et al., 2001) . Therefore, there is a need to identify and validate novel therapeutic targets that could interfere with Ewing's sarcoma growth or metastasis.
Platelet-derived growth factor (PDGF) is an important mitogen and chemoattractant secreted into the serum by a variety of cells (Heldin et al., 1998) . There are two well-characterized PDGF ligands, PDGF-A and PDGF-B. These form homodimers as PDGF-AA and PDGF-BB as well as a heterodimer of PDGF-AB (Williams, 1989) . Recently two new members of this family have been discovered, named PDGF-C and PDGF-D (Li et al., 2000; Bergsten et al., 2001; Gilbertson et al., 2001; LaRochelle et al., 2001) . PDGF-A and PDGF-B chains are secreted from the cell as mature ligands, whereas PDGF-C and PDGF-D require proteolytic cleavage outside the cell to become active. PDGF ligands exert their effect on target cells through specific dimeric receptors (Heldin et al., 1998) . The two different subunits of PDGF receptors (PDGFR) have different ligand binding specificity. a-PDGFR binds PDGF-A, -B and -C chains, but b-PDGFR binds only PDGF-B and PDGF-D chains. PDGF-C has an affinity towards a-PDGFR similar to PDGF-A, and PDGF-D has an affinity towards b-PDGFR similar to PDGF-B. Ligand binding initiates dimerization and autophosphorylation of the specific receptors. Tyrosine-phosphorylated residues on the intracytoplasmic domain of the receptor recruit secondary signaling molecules including, PLC-g, PI3Kp85, GAP, Src, SHP-2 and Shc, which are also phosphorylated by the tyrosine kinase domain of the PDGFR (Williams, 1989; Heldin et al., 1998) .
PDGF has important roles in physiologic processes including embryonic development, wound healing, angiogenesis, hemostasis and platelet aggregation. Overactivity of the PDGF signaling contributes to the pathogenesis of many diseases including lung fibrosis, glomerulonephritis, atherosclerosis and cancer ). The PDGF-B homolog, v-sis, was one of the earliest discovered oncogenes (Doolittle et al., 1983; Waterfield et al., 1983) . Overexpression of PDGF ligands and receptors has been reported for many solid tumors including glioblastoma, meningioma, melanoma, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer and gastric carcinoma ). Owing to the therapeutic potential of this pathway, there is an active effort to develop strategies to inhibit receptor function, which includes antagonists of receptor-ligand interaction, receptor dimerization and receptor tyrosine kinase (Kovalenko et al., 1994; Buchdunger et al., 1995) .
The cytokine signaling networks of ESFT have begun to be elucidated. For example, insulin-like growth factor (IGF-1) signaling is essential for tumorigenesis (Toretsky et al., 1997) and maintenance of tumor growth (Scotlandi et al., 1998) . Recently, PDGF-C expression has been reported in Ewing's sarcoma cell lines (Zwerner and May, 2001 ). However, there has been no characterization of PDGF receptor types or signaling pathways in ESFT. We present evidence that ESFT cell lines express functional b-PDGFR but not a-PDGFR, suggesting paracrine stimulation rather than an autocrine loop. We also show the presence of b-PDGFR on patient tumors.
Results

ESFT cell lines express only the b-subunit of PDGFR
PDGFR signaling has been shown to modulate tumor growth by autocrine or paracrine stimulation and ligand-independent constitutive activation in some tumors. Even though the PDGF pathway has been studied in many tumor types, there has been no report of PDGF signaling in ESFT. A recent publication provided evidence that ESFT cell lines express the ligand PDGF-C (Zwerner and May, 2001) . Therefore, we sought to investigate the existence of PDGF receptors in ESFT cell lines and tumor samples. Previously established ESFT cell lines were tested for the expression of PDGF receptors by Western blotting (Figure 1a) . b-PDGFR expression was detected in eight of the nine cell lines tested; TC-32, TC-71, MHH-ES-1, A4573, 6647, RD-ES, SK-ES and ES-295. Interestingly, none of the cell lines expressed detectable a-PDGFR protein (Figure 1b) .
The presence of b-PDGFR and the absence of a-PDGFR in ESFT cell lines were also confirmed by cellular response to PDGF ligands. ESFT cell lines were serum starved for 16 h and then exposed to PDGF-AA and PDGF-BB. Cell lysates were analysed for tyrosine phosphorylation levels of PDGF receptor signaling components by immunoprecipitation and immunoblotting ( Figure 1c ). All eight cell lines that were found to express b-PDGFR were also responsive to PDGF-BB stimulation in the form of PLC-g phosphorylation. None of the cell lines showed any detectable response to PDGF-AA stimulation. A similar pattern of phosphorylation was detected when the membranes were blotted with b-PDGFR, PI3Kp85 and Shc antibodies (data not shown). PDGF-AA did induce phosphorylation of PLC-g, PI3Kp85 and Shc in a control fibroblast cell line (data not shown). Taken together, these results confirm that ESFT cell lines do not express any detectable a-PDGFR but do express functional b-PDGFR protein. Since PDGF-C ligand only signals through aa-PDGFR homodimers or ab-PDGFR heterodimers and Ewing's cells do not express any a-PDGFR, therefore, it is likely that PDGF-C expression in Ewing's sarcoma does not cause autocrine signaling. However, it could still play a crucial role by its effect on tumor stromal tissue, especially by inducing tumor angiogenesis to maintain an adequate blood supply to a fast-growing solid tumor.
ESFT tumor samples from patients express b-PDGFR
Archived ESFT patient samples were evaluated for b-PDGFR by immunohistochemistry (Figure 2 ). ESFT (TC-32) tumors grown in nude mice were used for optimization of antibody dilutions and incubation conditions (Figure 2a) . In order to evaluate the background staining because of secondary antibody, sections from the same tumor were processed without the primary antibody (Figure 2b ). We then analysed pathological specimens from 52 ESFT patients; 10 of them on individual slides and 42 of them on a single slide in the form of a tissue microarray. Sections from paraffin blocks were immunostained with CD99-and b-PDGFR-specific antibodies. The presence of CD99 staining at the plasma membrane of all samples, along with molecular pathological assessment in most cases, confirmed their ESFT diagnoses. A representative sample is presented in Figure 2c and d. Among the tested tumor samples, 90% (47/52) showed significant membrane staining. Expression of b-PDGFR not only on ESFT cell lines but also on tumors from patients suggests that PDGFR signaling might play a role in the development or maintenance of these neoplastic cells.
b-PDGFRs expressed on ESFT cell lines are biologically functional
b-PDGFR function on ESFT cells was assessed based on the activation of b-PDGFR and its downstream signaling components, PLC-g, PI3Kp85 and Shc (Figure 3a, b) . Time course studies of receptor activation in response to the ligand showed that serum-starved TC-32 cells stimulated with 50 ng/ml PDGF-BB exhibited receptor activation as early as 2 min (Figure 3a) . Activation was detected in the form of tyrosine-phosphorylated b-PDGFR. Activated receptor levels returned to untreated levels after 1 h. PDGF-BB induced activation of secondary signaling components was also detected in the same experimental setting (Figure 3b ). Tyrosine phosphorylation of PLC-g, PI3Kp85 and Shc was detected in TC-32 cell lysates after 2 min of PDGF-BB stimulation. PDGF-AA stimulation did not produce the same effect because of the lack of a-PDGFR despite a time course from 2 to 60 min in this cell line (data not shown). Since a-PDGFR can be stimulated by either PDGF-AA or PDGF-BB and b-PDGFR can be stimulated by PDGF-BB but not PDGF-AA, these results confirm that Ewing's cells only express b-PDGFR. Moreover, these b-PDGFRs have full biochemical activity to transmit signals through downstream phosphotyrosine activation, thus providing evidence for intact and functional PDGFR signaling in ESFT.
PDGF-BB induces motility of ESFT cells through b-PDGFRs
In vitro chemotaxis experiments model cellular migration, which is necessary for tumor invasion and metastasis. A physiologic effect of PDGFR signaling was measured by the chemotaxis of ESFT cell lines (Figure 3c, d ). TC-32 cells migrated through a porous membrane in response to PDGF-BB in a dose-dependent manner. Optimum chemotaxis was observed with a dose of 50 ng/ml PDGF-BB. In agreement with the biochemical data, TC-32 cells migrated towards PDGF-BB but not towards Cell lysates from ESFT cell lines were subjected to immunoprecipitation with an antibody against a-PDGFR and analysed by Western blot using another a-PDGFR antibody. A human osteosarcoma cell line (SAOS) is used as a positive control for the expression of a-PDGFR. Standard molecular weight markers in kDa are displayed on the left. Arrow and arrowhead indicate mature and immature forms of a-PDGFR, respectively. (c) ESFT cell lines were serum starved for 16 h and stimulated with 50 ng/ml PDGF-BB (b), 50 ng/ml PDGF-AA (a) or untreated (À) for 2 min. Cell lysates were subjected to immunoprecipitation with a phosphotyrosine antibody followed by Western blotting with a PLC-g antibody. Arrowhead indicates the band corresponding to 148 kDa PLC-g protein PDGF-AA (Figure 3d ). On the other hand, a control cell line, NIH-3T3, that expresses both types of PDGFRs migrated towards both ligands (data not shown). It is therefore possible that b-PDGFRs regulate cell migration and might be involved in tissue invasion and metastasis in patients with ESFT.
PDGF-BB augments growth of ESFT cells
PDGF, especially BB isoform, is a very strong mitogen for many cell types and it is available in the serum at high concentrations. We were not able to detect a positive effect of PDGF-BB on TC-32 cells in classical mitogenic assays (data not shown).
However, when the cells were grown in matrigel, PDGF-BB showed a significant growth-enhancing potential (Figure 4 ). In the absence of serum, TC-32 cells form very few colonies in matrigel and they are very small in size. Addition of 10% fetal bovine serum (FBS) increased colony size by 16-fold and number of colonies by fourfold. PDGF-BB alone in serum-free media increased colony size by sevenfold and number of colonies by twofold. In an in vitro assay, PDGF-BB was able to mimic 50% of serum effect. Therefore, high levels of PDGF from serum and local sources like endothelial cells could contribute to accelerated growth of ESFT tumors in patients.
Specific PDGFR inhibitor abolishes PDGF-BB induced receptor activation and cell motility in ESFT cells
We examined the effects of an established PDGFR tyrosine kinase inhibitor, AG1295, on TC-32 PDGFR activation, survival and chemotaxis ( Figure 5 ). Prior to PDGF-BB stimulation, cells were serum starved for 16 h and exposed to different concentrations of AG1295 in serum-free media for 5 h as indicated in Figure 5a . Following ligand stimulation for 2 min, tyrosine phosphorylation levels of b-PDGFR and its downstream signaling components were analysed by immunoprecipitation and immunoblotting. Activation of b-PDGFRs was significantly abrogated by 10 mm 10AG1295. Similarly, PDGF-BB-dependent tyrosine phosphorylation of PLC-g, PI3Kp85 and Shc was also inhibited by AG1295 treatment (Figure 5a ). Inhibition of b-PDGFR by AG1295 was also observed as diminished TC-32 chemotaxis towards PDGF-BB ligand (Figure 5b ).
Specific PDGFR inhibitor blocks ESFT cell growth in vitro and slows down tumor growth in vivo
To examine the effect of AG1295 on cell growth, TC-32 cells were grown in 96-well plates in the presence of 10% FBS and increasing concentrations of AG1295 as indicated in Figure 5c . After 7 days of culture, viable cells were measured by MTT assay. Results indicate that The ability of AG1295 to impact in vivo growth of ESFT tumors was tested using a xenograft model. Tumors were established in immunocompromised mice by intramuscular injection of TC71 ESFT cells as described in the Materials and methods. Treatment with AG1295 at 2 or 6 mg/kg/day was initiated 7 days following tumor injection. Animals treated with high-or low-dose AG1295 had a significant delay in the time to tumor development when compared to animals treated with vehicle alone (Figure 6 ). The animals treated with 6 mg/kg/day AG1295 showed both a delay in tumor development and an improved overall survival. In fact, four out of 15 mice (26%) never developed tumor while being treated on this dose of AG1295 and continued to be tumor free at 16 weeks following tumor injection. The data from three mice were censored because of deaths attributable to toxicity during treatment. In the low-dose arm, two mice were found dead on experiment days 14 and 16, while one mouse died on day 23 in the high-dose arm. There were no gross abnormalities or tumor found on necropsy of any of these animals. The ability of AG1295 to block cell growth in vitro and tumor growth in vivo is a promising finding, which highlights b-PDGFR as a potential therapeutic target in ESFT treatment.
Discussion
Cytokine signaling is critical for the growth of ESFT cells, especially IGF-1 (Yee et al., 1990; van Valen et al., 1992; Toretsky et al., 1997; Ricotti et al., 1998; Scotlandi et al., 1998; Girnita et al., 2000; Sanceau et al., 2000) . Our demonstration of functional b-PDGFR in ESFT cell lines as well as expression of this receptor in ESFT tumor specimens suggest a role for this signaling pathway in the ESFT phenotype. b-PDGFR in ESFT may contribute towards tumor proliferation and metastasis. Ligands, PDGF-B or PDGF-D, which are known to stimulate b-PDGFR do not appear to be secreted from the tumor cells, since conditioned media collected from ESFT cell lines did not activate b-PDGFR (data not shown). Additionally, lack of receptor autophosphorylation in unstimulated cells suggests that ESFT does not express PDGF-B or PDGF-D. Since PDGF-BB is one of the most abundant growth factors found in A recent publication presented data that the ESFT fusion protein EWS/FLI1 induces the expression of PDGF-C (Zwerner and May, 2001 ), which they hypothesized could lead to autocrine stimulation. However, their study did not provide any information regarding the status of PDGF receptor isoforms in ESFT. Since PDGF-C can only function through a-PDGFR (Li et al., 2000; Gilbertson et al., 2001 ), and we have not detected a-PDGFR expression in nine ESFT cell lines, our data suggest that such an autocrine pathway does not exist for PDGF-C in ESFT. It is more likely that PDGF-C is secreted by ESFT cells to exert an effect upon tumor stroma or vasculature by a paracrine mechanism, since both fibroblasts and endothelial cells express a-PDGFR.
We have used a relatively specific tyrosine kinase inhibitor, AG1295, in our studies. The IC 50 of AG1295 was calculated to be 4 mm in our biochemical and chemotaxis experiments in contrast to 20 mm in growth assays. This discrepancy is reasonable, since tyrphostins are bound to serum proteins and have reduced activity in the presence of serum (Bryckaert et al., 1992) . Since biochemical signaling as well as chemotaxis experiments were performed in serum-free media and the growth assays utilized 10% serum for optimal cell growth, we believe that the fivefold difference in IC 50 was because of protein binding. Similarly, AG1295 bioavailability and pharmacokinetics make it difficult to estimate the local concentration of drug in our in vivo studies. Nevertheless, AG1295 was able to delay tumor formation in immunocompromised mice and significantly improve overall survival. Stem cell factor receptor (KIT) is expressed on ESFT cells (Ricotti et al., 1998) and KIT is inhibited by AG1295 with a lower K d (Kovalenko et al., 1994) . However, its higher affinity for b-PDGFR suggests that b-PDGFR was primarily affected. Gleevec (imatinib mesylate, STI-571) is a tyrosine kinase inhibitor that has been clinically useful in gastrointestinal stromal tumors, which express constitutively activated KIT (van Oosterom et al., 2001) , but is also known to inhibit b-PDGFR. A similar approach with more specific agents could be beneficial in ESFT too.
Our demonstration of biologically active b-PDGFRs suggests that PDGF signaling may play a significant role in the proliferation and metastasis of ESFT. Thus, PDGF signaling may provide a therapeutic target in ESFT. In addition, further characterization of PDGFRs in patients might yield prognostic information. Utilizing current and developing novel strategies to target b-PDGFR signaling in patients with ESFT might improve survival, particularly, for those patients with metastatic disease.
Materials and methods
Recombinant human PDGF-AA and PDGF-BB proteins and antiphosphotyrosine antibody were obtained from Upstate Biotechnology (Lake Placid, NY, USA). Anti-a-PDGFR antibody for immunoprecipitation and western blotting were purchased from BD Biosciences Pharmingen (San Diego, CA, USA) and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, Figure 6 PDGFR tyrosine kinase inhibitor, AG1295, slows Ewing's sarcoma tumor growth in vivo and improves overall survival. Xenografts were established with TC71 Ewing's sarcoma cells in SCID/bg mice as described. Therapy was begun on day 7 with daily intraperitoneal injections of AG1295 at 6 mg/kg/day (n ¼ 15 mice), AG1295 at 2 mg/kg/day (n ¼ 10 mice) or vehicle alone (n ¼ 15 mice) given for 5 days followed by 2 days rest for a total of three cycles. Kaplan-Meier curves represent tumor-free survival from two individual experiments. *P ¼ 0.044; **P ¼ 0.008 both vs vehicle by one-way analysis of variance. All statistical tests were two sided USA), respectively. Anti-b-PDGFR antibodies for Western blotting and immunohistochemistry were purchased from BD Biosciences Pharmingen (San Diego, CA, USA) and Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), respectively. Anti-CD99 (Clone 12 E7) antibody was purchased from Dako Corporation (Carpinteria, CA, USA). PDGFR kinase inhibitor tyrphostin AG1295 was obtained from Alexis Biochemicals (San Diego, CA, USA). Anti-PLC-g, antiPI3Kp85 and anti-Shc antibodies were purchased from BD Transduction Laboratories (Lexington, KY, USA). Unless stated otherwise, all chemical reagents were purchased from Sigma (St Louis, MO, USA). ESFT cell lines have been previously reported (Kontny et al., 1998) except ES 925, which was shown to have a type I-EWS/FLI1 translocation by RT-PCR (data not shown). Immunoprecipitations and Western blottings were done as described previously (Uren et al., 2000) . Chemotaxis experiments were done as reported earlier (Uren et al., 1994) . Briefly, 5 Â 10 5 TC-32 cells were added to Boyden chambers containing 8 mm polycarbonate filter and chemoattractants. Following an overnight incubation at 371C, filters were washed and fixed in 10% formalin for 20 min. Filters were then washed with water and stained with 0.5% crystal violet/25% methanol for 60 min. Following three times water wash, the cells on the upper surface were scraped off. Crystal violet staining remaining on the filter was dissolved in 300 ml 0.1 m citric acid/50% ethanol and absorbance at 595 nm was measured. Matrigel assays were performed in 24-well plates. Wells were first coated with 200 ml Matrigelt matrix (BD Biosciences, Bedford, MA, USA). Cells were then added in an additional 200 ml Matrigelt matrix at 6 Â 10 4 cells/well density. Following matrix solidification, RPMI, RPMI with 10% FBS and RPMI with 50 ng/ml PDGF-BB were added at 500 ml/well volume. After 7 days incubation, black and white digital images were obtained by a stereoscope at low magnification. Number of colonies and their size were determined by using MetaMorph image analysis software (Universal Imaging Corp., Dowingston, PA, USA). Cell survival experiments were done in 96-well plates with 5 Â 10 3 TC-32 cells/well. Cultures were grown for 7 days in RPMI with 10% FBS and the indicated concentrations of AG1295. Media with and without drug were changed every other day. In order to determine cell viability, 0.5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide thiazolyl blue (MTT) was added into each well and incubation continued for 3 h. Plates were briefly centrifuged, all media removed and air-dried overnight. Dye in each well was dissolved in 100 ml isopropanol and absorbance was measured at 405 nm wavelength. Immunohistochemistry was performed on 5 mm sections of formalin-fixed, paraffinembedded tissue from patients with diagnosed ESFT. Informed consent was obtained for laboratory studies at the time of the surgery. Antigen retrieval occurred by steam heat for 20 min, followed by a standard avidin-biotin peroxidase complex technique, and automated immunostaining (Ventana Medical System, Tucson, AZ, USA). The primary antibody was rabbit anti-human b-PDGFR diluted 1 : 50 (Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA) and the secondary antibody was biotinylated-mouse anti-rabbit antibody (Ventana Medical System, Tucson, AZ, USA). TC-32 cells that were already shown to express b-PDGFRs is used as a positive control in the immunohistochemistry studies. Subcutaneous injection of 1 Â 10 6 cells was used to generate a tumor mass in a nude mouse. A palpable tumor that appeared around 20 days postinjection was dissected out fixed and sectioned as a routine pathology specimen. Optimum primary and secondary antibody dilutions and wash conditions were generated on these preparations and were used on patient samples. As a negative control in immunohistochemistry experiments, a duplicate section was processed without the primary antibody. A highdensity Ewing's sarcoma tissue microarray block was made at MSKCC using a tissue arrayer (Beecher Instruments, Silver Spring, MD, USA) and contained triplicate 0.6 mm cores of 67 tumor samples from 60 patients with Ewing's sarcoma, along with a variety of control tissues. All tumors were previously confirmed by RT-PCR to have either the EWS-FLI1 or EWS-ERG gene fusion. Donor paraffin blocks for all arrayed tumors were verified histologically prior to use. Immunohistochemistry stains with anti-CD99 and anti-b-PDGFR on sections from the tissue microarray were performed as described above and were scored by a pathologist (CJ Sun). Samples from 18 patients were not scored owing to lack of tumor in the section or loss of tissue from the microarray slide. In vivo tumor growth TC71 Ewing's sarcoma tumor cells were cultured to a confluence of 75-90%, harvested with trypsin/ EDTA, and then washed twice with PBS. One million cells were injected in 100 ml of PBS into the gastrocnemeius of 4-to 12-week-old SCID/bg mice (Taconic, Germantown, NY, USA). On day 7 following tumor injection, mice were randomly assigned to receive intraperitoneal injections with 6 mg/kg/day Tyrphostin AG1295 (Alexis Biochemicals, San Diego, CA, USA) 2 mg/kg/day AG1295 or vehicle alone (phenol red-free RPMI+10% DMSO+10% FCS). Therapy was given daily for 5 days followed by a 2 day rest and continued for a total of 3 weeks. Tumor dimensions were measured every 1-2 days with digital calipers to obtain two diameters of the tumor sphere. The lower extremity volume at the site of the tumor was determined by the formula (D Â d 2 / 6)p, where D is the longer diameter and d is the shorter diameter. Lower extremity volumes without tumor were approximately 50 mm 3 . Mice were no longer considered to be tumor free when a palpable tumor with a volume greater than 100 mm 3 was obtained followed by a larger volume noted on the next measurement. Xenograft studies were approved by the NCI Animal Care and Use Committee and all animal care was in accordance with institutional guidelines.
